Anika Therapeutics | ANIK - Umsatzerlöse

Aktienkurs
14.69
Täglich Wechseln
-0.26 -1.74%
Monatlich
-1.54%
Jährlich
1.38%
Q2 Prognose
14.54




Der Umsatz Veränderung Datum
Abbott USD 11.16B 300M 2026-03
Agenus USD 34.2M 3.97M 2025-12
Agios Pharmaceuticals USD 18.8M 1.17M 2026-03
Anika Therapeutics USD 30.62M 2.8M 2025-12
Arrowhead Research USD 264.03M 7.56M 2025-12
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Halozyme Therapeutics USD 451.76M 97.76M 2025-12
Heron Therapeutics USD 40.59M 2.38M 2025-12
Insmed USD 263.8M 121.8M 2025-12
Integra LifeSciences USD 391.9M 43M 2026-03
Intrexon USD 717K 511K 2024-06
J&J USD 24.1B 500M 2026-03
Karyopharm Therapeutics USD 34.08M 3.54M 2025-12
Ligand Pharmaceuticals USD 59.66M 55.8M 2025-12
MacroGenics USD 41.23M 31.61M 2025-12
Merit Medical Systems USD 381.9M 12M 2026-03
Rigel Pharmaceuticals USD 55.31M 18.47M 2024-09
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 11.24B 60M 2026-03
Smith & Nephew USD 3.18B 353M 2025-12
Stryker USD 6B 1.2B 2026-03
Surmodics USD 29.57M 355K 2025-06
Veracyte USD 139.07M 1.53M 2026-03
Xencor USD 28.24M 7.24M 2025-12
Zimmer Biomet Holdings USD 2.09B 150M 2026-03